Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending March 2012. The report serves as a notification of transactions involving directors and persons discharging managerial responsibility (PDMRs). Specifically, it details the grant of conditional share awards on March 9, 2012, under the 2009 Performance Share Plan (PSP) and the 2009 Deferred Annual Bonus Plan (DABP).
Key Financial Metrics
The filing does not report operational financial results such as revenue, profit, cash flow, margins, debt, or liquidity for the period. Instead, it discloses specific financial thresholds used as performance targets for executive compensation:
- Adjusted Free Cash Flow Target: Vesting thresholds range from £17.30 billion (25% vesting) to £20.52 billion (100% vesting).
- Share Pricing: Awards were valued using an Ordinary Share price of £14.12 (London Stock Exchange) and an ADS price of US$44.68 (New York Stock Exchange) as of March 8, 2012.
Material Changes and Performance Measures
The filing outlines the structure of new executive incentives effective for the performance period of January 1, 2012, to December 31, 2014. The awards are based on four equally weighted performance measures (25% each):
- Total Shareholder Return (TSR): Relative performance against a comparator group of 10 global pharmaceutical companies. No vesting occurs below the median; 100% vests at the upper quartile.
- Adjusted Free Cash Flow: Absolute targets set between £17.30 billion and £20.52 billion.
- R&D New Product: Targets are undisclosed due to commercial sensitivity. Vesting ranges from 25% at threshold to 100% at 122% of the threshold.
- Business Diversification: Targets are undisclosed due to commercial sensitivity. Vesting ranges from 25% at threshold to 100% at 114% of the threshold.
Guidance, Outlook, and Risks
Management Commentary and Outlook: The filing indicates a strategic focus on simplifying the operating model, delivering R&D value, and growing a diversified global business. Specific R&D and diversification targets are withheld until the end of the performance period.
Risks and Contingencies:
- Vesting Risk: If performance thresholds are not met, awards will lapse entirely for the specific measure.
- CEO Holding Period: Sir Andrew Witty's award includes a unique contingency where 25% of the award is subject to an additional two-year holding period post-vesting. These shares would be forfeited if he is terminated for cause.
- Market Risk: The value of the awards is contingent on share price performance relative to peers.
Investor Verification Checklist
- Verify the specific R&D and business diversification targets once disclosed at the end of the 2014 performance period.
- Monitor GSK's adjusted free cash flow against the £17.30 billion to £20.52 billion vesting range.
- Track GSK's Total Shareholder Return relative to the defined comparator group (Abbott, AstraZeneca, BMS, Eli Lilly, J&J, Merck, Novartis, Pfizer, Roche, Sanofi).
- Confirm the final vesting outcomes for Executive Directors, particularly the additional holding period conditions for Sir Andrew Witty.